Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy

American Journal of Medicine

Volumn 118, Issue 12, 2005, Pages 1414.e21-1414.e27

  Leung, Wilson Y S ^a   So, Wing Yee ^a   Tong, Peter C Y ^a   Chan, Norman N ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetic nephropathy; Disease management; Health care delivery; Renoprotection; Structured care

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

EID: 29244439909     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.07.050     Document Type: Article

References (31)

1. E. Ritz, I. Rychlik, F. Locatelli, S. Halimi End-stage renal failure in type 2 diabetes a medical catastrophe of worldwide dimensions Am J Kidney Dis 34 1999 795 808
2. H.H. Parving, A.R. Andersen, U.M. Smidt, E. Hommel, E.R. Mathiesen, P.A. Svendsen Effect of antihypertensive treatment on kidney function in diabetic nephropathy Br Med J (Clin Res Ed) 294 1987 1443 1447
3. C. Hasslacher, A. Bostedt-Kiesel, H.P. Kempe, P. Wahl Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 1051 1056
4. L. Fried, T. Orchard, B. Kasiske Lipids and Renal Disease Progression Meta-analysis Study Group Effect of lipid reduction on the progression of renal disease a meta analysis Kidney Int 59 2001 260 269
5. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
6. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
7. F. Chantrel, I. Enache, M. Bouiller Abysmal prognosis of patients with type 2 diabetes entering dialysis Nephrol Dial Transplant 14 1999 129 136
8. E.J. Dunn, C.J. Burton, T.G. Feest The care of patients with diabetic nephropathy audit, feedback, and improvement QJM 92 1999 443 449
9. G. Ellrodt, D.J. Cook, J. Lee, M. Cho, D. Hunt, S. Weingarten Evidence-based disease management JAMA 278 1997 1687 1692
10. T.G. Feest, E.J. Dunn, C.J. Burton Can intensive treatment alter the progress of established diabetic nephropathy to end-stage renal failure? QJM 92 1999 275 282
11. N. Joss, K.R. Paterson, C.J. Deighan, K. Simpson, J.M. Boulton-Jones Diabetic nephropathy how effective is treatment in clinical practice? QJM 95 2002 41 49
12. American Diabetes Association Position statement. Diabetic nephropathy Diabetes Care 25 2002 s85 s89
13. E. Kaplan, P. Meier Nonparametric estimation for incomplete observations J Am Stat Assoc 53 1958 457 481
14. D.R. Cox Regression models and life-tables J R Stat Soc Ser B 34 1972 187 202
15. D.G. Altman, P.K. Andersen Calculating the number needed to treat for trials where the outcome is time to an event Br Med J 319 1999 1492 1495
16. I. Kreft, J. de Leeuw Introducing Multilevel Modeling 1st edn. 1998 SAGE Publications Ltd London, UK
17. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, H. Keen Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes Diabetologia 44 9 Suppl 2 2001 S14 S21
18. American Diabetes Association Position statement. Standards of medical care for patients with diabetes mellitus Diabetes Care 25 2002 s33 s49
19. J.M. Rimmer, J.F. Horn, F.J. Gennari Hyperkalemia as a complication of drug therapy Arch Intern Med 147 1987 867 869
20. D.E. Hricik, P.J. Browning, R. Kopelman, W.E. Goorno, N.E. Madias, V.J. Dzau Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney N Engl J Med 308 1983 373 376
21. 1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients Diabetes Care 22 1999 1785 1789
22. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 Br Med J 317 1998 703 713
23. L. Hansson, A. Zanchetti, S.G. Carruthers HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1998 1755 1762
24. L.S. Morris, R.M. Schulz Patient compliance - an overview J Clin Pharm Ther 17 1992 283 295
25. S.A. Oliveria, P. Lapuerta, B.D. McCarthy, G.J. L'Italien, D.R. Berlowitz, S.M. Asch Physician-related barriers to the effective management of uncontrolled hypertension Arch Intern Med 162 2002 413 420
26. P.E. Bogden, R.D. Abbott, P. Williamson, J.K. Onopa, L.M. Koontz Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension J Gen Intern Med 13 1998 740 745
27. W.F. Keane, A. Polis, D. Wolf, E. Faison, S. Shahinfar The long-term tolerability of enalapril in hypertensive patients with renal impairment Nephrol Dial Transplant 12 Suppl 2 1997 75 81
28. Y. Wang, M.C. Ng, W.Y. So Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes Diabetes Care 28 2005 348 354
29. K. Benson, A.J. Hartz A comparison of observational studies and randomized, controlled trials N Engl J Med 342 2000 1878 1886
30. J. Concato, N. Shah, R.I. Horwitz Randomized, controlled trials, observational studies, and the hierarchy of research designs N Engl J Med 342 2000 1887 1892
31. M. McKee, A. Britton, N. Black, K. McPherson, C. Sanderson, C. Bain Methods in health services research. Interpreting the evidence choosing between randomised and non-randomised studies Br Med J 319 1999 312 315